ECSP12012031A - Composición farmacéutica que comprende oligopéptidos - Google Patents

Composición farmacéutica que comprende oligopéptidos

Info

Publication number
ECSP12012031A
ECSP12012031A ECSP12012031A ECSP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
oligopeptides
includes oligopeptides
lipophilic
amphiphilic
Prior art date
Application number
Other languages
English (en)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP12012031A publication Critical patent/ECSP12012031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de oligopéptidos, con preferencia oligopéptidos cíclicos, en donde dicha composición también comprende uno o varios compuestos lipofílicos y/o anfifílicos, en presencia o ausencia de agua como los ingredientes principales, al uso de los compuestos lipofílicos y/o anfifílicos para preparar composiciones farmacéuticas de dichos oligopéptidos y a métodos de preparación de tal composición farmacéutica.
ECSP12012031 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos ECSP12012031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
ECSP12012031A true ECSP12012031A (es) 2012-08-31

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012031 ECSP12012031A (es) 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos

Country Status (20)

Country Link
US (1) US9433577B2 (es)
EP (1) EP2509583B1 (es)
JP (1) JP5946770B2 (es)
KR (1) KR20120104316A (es)
CN (1) CN102652015B (es)
AU (1) AU2010330364B2 (es)
BR (1) BR112012012862A2 (es)
CA (1) CA2783732A1 (es)
CL (1) CL2012001310A1 (es)
EA (1) EA022700B1 (es)
EC (1) ECSP12012031A (es)
ES (1) ES2742263T3 (es)
IL (1) IL220097A (es)
MX (1) MX2012006450A (es)
NZ (1) NZ601109A (es)
PE (1) PE20121359A1 (es)
PH (1) PH12012500754A1 (es)
SG (1) SG181487A1 (es)
WO (1) WO2011069629A2 (es)
ZA (1) ZA201205103B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022831B1 (ru) 2009-05-20 2016-03-31 Мерк Патент Гмбх Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012167870A1 (en) * 2011-06-09 2012-12-13 Merck Patent Gmbh Treatment of cancers and metastases with suspensions of cilengitide in carrier
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
EP3810182A4 (en) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigens and uses thereof
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108266C (en) 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
PT100723A (pt) * 1991-07-26 1993-08-31 Smithkline Beecham Corp Microemulsoes de agua em oleo,auto-emulsionantes, estaveis e farmaceuticamente aceitaveis e seu uso
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
PT1435910E (pt) 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
EP1628641A2 (en) 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
ES2313352T3 (es) * 2004-06-03 2009-03-01 Bracco Research S.A. Ensamblaje de liposomas para uso terapeutico y/o diagnostico.
CA2699177A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2259768B1 (en) * 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
EA022831B1 (ru) * 2009-05-20 2016-03-31 Мерк Патент Гмбх Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения

Also Published As

Publication number Publication date
CN102652015A (zh) 2012-08-29
AU2010330364B2 (en) 2016-05-19
KR20120104316A (ko) 2012-09-20
JP5946770B2 (ja) 2016-07-06
WO2011069629A2 (en) 2011-06-16
ZA201205103B (en) 2013-03-27
CN102652015B (zh) 2016-08-03
WO2011069629A3 (en) 2012-03-15
EP2509583A2 (en) 2012-10-17
ES2742263T3 (es) 2020-02-13
MX2012006450A (es) 2012-06-28
SG181487A1 (en) 2012-07-30
PE20121359A1 (es) 2012-10-15
CL2012001310A1 (es) 2012-10-12
CA2783732A1 (en) 2011-06-16
EA201200850A1 (ru) 2013-01-30
IL220097A (en) 2017-03-30
AU2010330364A1 (en) 2012-07-26
US20120288539A1 (en) 2012-11-15
NZ601109A (en) 2014-06-27
JP2013513556A (ja) 2013-04-22
US9433577B2 (en) 2016-09-06
BR112012012862A2 (pt) 2016-08-16
EP2509583B1 (en) 2019-05-15
PH12012500754A1 (en) 2018-03-21
EA022700B1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
ECSP12012031A (es) Composición farmacéutica que comprende oligopéptidos
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
ECSP12011939A (es) Compuestos Lipopéptidos y métodos relacionados
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP12011935A (es) Triazolopiridinas
MX2013003365A (es) Composicion farmaceutica.
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
DOP2014000133A (es) Triazolopiridinas sustituidas
CO6650348A2 (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
MX2012008717A (es) Composiciones para el cuidado oral.
CR20120357A (es) Composición que comprende un pesticida y un alcoxilato de 2-propilheptilamina
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
CR11755A (es) Dronedarona para la prevencion de la cardioversion
AR075228A1 (es) Composiciones para el tratamiento del cabello.
NZ610950A (en) Pharmaceutical compositions comprising alisporivir
IT1398875B1 (it) Composizioni contenti l. mucosae per uso medico.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012007172A (es) Piperazinas como agentes antimalaria.